With total federal support exceeding $52M, RIVANNA accelerates development of CADe/x — an AI-driven diagnostic tool poised to transform musculoskeletal care through automated ultrasound image analysis and real-time fracture triage. ...
Strategic collaboration aims to accelerate validation and commercialisation of non-invasive tests, enabling earlier, more accessible diagnosis of Alzheimer’s disease ...
Strategic relocation from Hong Kong strengthens ties to Asia’s thriving MedTech ecosystem, enhances collaboration with global partners, and supports ambitious expansion plans ...
AI-powered, patient-matched solution aims to simplify Lapidus procedures and enhance surgical outcomes...
Partnership aims for CAP/CLIA certification of organoid-based assay to guide patient-specific treatment decisions; $10 million investment to fuel clinical validation across multiple cancer types ...
By aligning regulatory rigour with technological complexity, the FDA safeguards public health while accelerating access to life-changing medical innovations through adaptive pathways and total lifecycle vigilance...
First and only purpose-built solution delivering rapid and complete luminal clot removal in small vessel and arteriovenous access cases...
First in the industry to achieve dual certification for both reagents and analysers within its Atellica portfolio...
Developed with PacBio's PureTarget technology, the new test enhances identification of complex DNA repeat expansions to support accurate diagnosis and care for patients with neurological disorders ...
Strategic alliance enhances in-home screening with advanced molecular diagnostics, AI-driven insights, and flexible testing options to improve outcomes for patients and underserved communities. ...
